

KING PHARMACEUTICALS INC
Form 15-12B
March 01, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission File Number 001-15875

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

501 Fifth Street

Bristol, Tennessee 37620

(423) 989-8000

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, no par value

1 1/4% Convertible Senior Notes Due 2026

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Edgar Filing: KING PHARMACEUTICALS INC - Form 15-12B

Rule 12g-4(a)(1)	x
Rule 12g-4(a)(2)	..
Rule 12h-3(b)(1)(i)	x
Rule 12h-3(b)(1)(ii)	..
Rule 15d-6	..

Approximate number of holders of record as of the certification or notice date:

Common Stock, no par value	1
1 1/4 % Convertible Senior Notes Due 2026	7

Edgar Filing: KING PHARMACEUTICALS INC - Form 15-12B

Pursuant to the requirements of the Securities Exchange Act of 1934, King Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: March 1, 2011

KING PHARMACEUTICALS, INC.

By: /s/ Bryan Supran
Name: Bryan Supran
Title: Vice President